ArticleOncotarget2017

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.

Liangshun You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.